Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models

Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases

(2022) Christoph Lange et al.   LANCET INFECTIOUS DISEASES

Rough and smooth variants of Mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish

(2022) Julia Y. Kam et al.   Nature Communications

Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue

(2022) Véronique Dartois et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Atypical mycobacterial infections – management – when to treat

(2021) Laura Indira Gill et al.   CURRENT OPINION IN PULMONARY MEDICINE

Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month

(2021) Amit K. Singh et al.   TUBERCULOSIS

Growth medium and nitric oxide alter Mycobacterium abscessus morphotype and virulence

(2021) Nishant Nandanwar et al.   MICROBIOLOGICAL RESEARCH

The potassium transporter KdpA affects persister formation by regulating ATP levels in Mycobacterium marinum

(2020) Xiaofan Liu et al.   Emerging Microbes & Infections

The Rise of Non-Tuberculosis Mycobacterial Lung Disease

(2020) Champa N. Ratnatunga et al.   Frontiers in Immunology

Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis

(2020) Fuzhen Zhang et al.   Infection and Drug Resistance

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary

(2020) Charles L Daley et al.   CLINICAL INFECTIOUS DISEASES

Reduction in Expected Survival Associated With Nontuberculous Mycobacterial Pulmonary Disease

(2020) Ahmad Mourad et al.   CLINICAL INFECTIOUS DISEASES

Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses

(2020) Aurélie Chauffour et al.   PLoS Neglected Tropical Diseases

In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis

(2019) Jian Xu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identifying regimens containing a new drug candidate TBI-166 against Mycobacterium tuberculosis in vitro and in vivo

(2019) Ye Zhang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pretomanid: First Approval

(2019) Susan J. Keam   DRUGS

Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease

(2018) Roland Diel et al.   CHEST

In vitro activity of PBTZ169 against multiple Mycobacterium species

(2018) Jin Shi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mortality among patients with pulmonary non-tuberculous mycobacteria disease

(2016) M. Fleshner et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model

(2016) J. P. Dalton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations

(2015) Claire Andréjak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bactericidal mode of action of bedaquiline

(2015) K. Hards et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evidence for the presence of clofazimine and its distribution in the healthy mouse brain

(2015) Sooraj Baijnath et al.   JOURNAL OF MOLECULAR HISTOLOGY

In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis

(2015) Norma Alejandra González-Martínez et al.   PLoS Neglected Tropical Diseases

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

(2014) V. Makarov et al.   EMBO Molecular Medicine

Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism

(2014) Anil Koul et al.   Nature Communications

Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

(2012) S. M. Batt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

(2008) S. P. S. Rao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA